Caleb Rans

Contributing Writer https://www.cancertherapyadvisor.com

Caleb Rans is a clinical pharmacist and medical communications specialist with professional expertise in medical writing, editing, and contract clinical research. He holds a PharmD from the University of Alberta and presently resides in Vancouver, Canada. He currently works as an independent consultant for several news, CME, and pharmaceutical companies.

All articles by Caleb Rans

SGO 2023

Uterine Cancer Mortality on the Rise, but Research Remains Underfunded

Caleb Rans

March 31, 2023

Though mortality rates for uterine cancer are on the rise, research for this cancer is underfunded, a study suggests.

News, SGO 2023

PIK3CA and ARID1A May Be Therapeutic Targets in Advanced Cervical Cancer

Caleb Rans

March 31, 2023

PIK3CA and ARID1A may be targets for drug development in recurrent or metastatic cervical cancer, according to researchers.

SGO 2023

Dostarlimab Plus Chemo Deemed New Standard Care for Endometrial Cancer

Caleb Rans

March 28, 2023

Adding dostarlimab to chemotherapy can improve outcomes in patients with primary advanced or recurrent endometrial cancer, a phase 3 trial suggests.

SGO 2023

Adding Anlotinib to Pembrolizumab Improves PFS in Ovarian Cancer

Caleb Rans

March 28, 2023

Anlotinib enhances the efficacy of pembrolizumab in patients with recurrent or refractory high-grade serous ovarian cancer, a phase 2 study suggests.

SGO 2023

Toripalimab, Bevacizumab, and Chemo Deemed Effective in Advanced Cervical Cancer

Caleb Rans

March 27, 2023

The combination of toripalimab, bevacizumab, and platinum-based chemotherapy appears safe and effective for patients with advanced cervical cancer.

SGO 2023

Reimbursement for Gynecologic Oncology Procedures Has Not Kept Up With Inflation

Caleb Rans

March 27, 2023

Physician reimbursement rates for gynecologic oncology procedures have increased in recent years but have not kept up with inflation, a study suggests.